The diagnostic procedure of chronic pulmonary opacities may envisage the se arch for non- to get histological diagnosis in primary pulmonary lymphoma, and by contrast would avoid the need for biopsy in the setting of a secondary pulmonary lymphoma.
Introduction
B-cell non-Hodgkin's lymphomas (B-NHL) are clonal lymphoproliferative malignancies primarily involving lymph nodes and the spleen (1) . Pulmonary localization of NHL can develop in two clinical settings, as primary pulmonary lymphoma or as pulmonary localization of a known extended lymphoma. Primary pulmonary lymphoma is an extranodal NHL defined by the involvement of the pulmonary parenchyma and the absence of any other tissue localization for three months following the diagnosis (2) . When the lung is the main tumor site, this definition also includes multifocal mucosa-associated lymphoid-tissue (MALT) NHL and pulmonary involvement with satellite nodes (hilar or mediastinal) (3).
Diagnosis requires biopsies by invasive methods such as transbronchial, percutaneous or even surgical lung biopsies (4, 5, and 6) for both histological analysis and immunohistological staining. More than 95% of primary pulmonary lymphomas are B-NHL (7, 8) with a predominance of low-grade lymphomas (75 to 80%), most of which consisting of mucosaassociated lymphoid tissue (MALT) lymphomas. High-grade malignant lymphomas represent 20 to 25% of primary pulmonary lymphomas (7, 9) . A secondary involvement of the lung from a known B-NHL is encountered (2) either at diagnosis leading to a stage IV disease (10), or during the course of the disease as progression or relapse.
The clinical and radiological abnormalities observed in pulmonary B-NHL are not specific (11) even if peri-bronchovascular interstitial thickenings on a CT scan may suggest the diagnosis (12, 13) . Atypical lymphocytes can be detected by cell morphology in bronchoalveolar lavage (BAL) fluid (14) but their detection is inconstant. Because lymphocytes could spread to the bronchoalveolar space, it has been suggested that the repertoire of lymphocyte recovered by bronchoalveolar lavage (BAL) could reflect the pulmonary infiltration repertoire. The phenotypic analysis of the lymphocytes in BAL fluid can detect a monotypic B-cell population (15) but CD8+ T-cells are more frequently dominant even in the presence of a pulmonary B-NHL (16, 17) leading to unhelpful conclusions.
The recent development of molecular biology techniques, Southern blotting (18) and Polymerase Chain Reaction (PCR) (19) , has provided the ability to detect a monoclonal population of B lymphocytes based on the detection of rearrangements of the genes that encode B-cell immunoglobulin receptor proteins. This has been applied to support the diagnosis of nodal (20, 21) or extra-nodal, for example gastric (22) and pulmonary (23, 24, 
25) B-NHL. The clonality of pulmonary lymphocyte infiltrates has been appreciated by
For personal use only. on October 17, 2017 . by guest www.bloodjournal.org From clonality analysis of alveolar lymphocytes. Detection of the same dominant B-cell clone in BAL fluid and lymphomatous pulmonary biopsy has been reported by Southern blot (26, 16, 15) , and in our more recent work, by PCR (17) , suggesting that alveolar lymphocytes clonality analysis could help in the diagnosis of pulmonary B-NHL involvement.
The aim of this study was to determine the feasibility of this procedure in routine practice, the sensitivity, specificity and predictive value of B-cell clonality in alveolar lymphocytes recovered by BAL for the diagnosis of pulmonary B-NHL. We studied a prospective cohort of 106 patients presenting with a clinical suspicion of pulmonary NHL.
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Patients and Methods

Patients and Study design
From January 1st 1994 to December 31st 1999, patients followed in the Department of Respiratory Diseases at Foch Hospital (Suresnes) and Tenon Hospital (Paris), were included in this bicentric prospective study. Patient management was as follows: patients admitted for the diagnosis of chronic pulmonary opacity (more than 3 weeks) underwent a first line standardized diagnostic procedure. It consisted of clinical and radiological evaluation, as well as bacteriological assessment of sputum. Thereafter, patients with a specific diagnosis were treated accordingly. Otherwise, a 10-days antibiotic therapy using beta-lactams or macrolides was instituted. Patients who did not respond to this treatment had bronchoscopy, Bronchoalveolar Lavage (BAL) and bronchial biopsies. In one of the two departments, transbronchial biopsies were obtained. An aliquot of 10 ml of lavage fluid was cultured for bacteria, mycobacteria, fungi and viruses. Different stainings of BAL smears were performed for cytological and opportunistic pathogens evaluation. In the absence of diagnosis within the first 72 hours, 10 ml of BAL fluid which were kept at 4°C were analyzed for B-cell clonality.
Inclusion criteria were: 1) one of the two following clinical situations: i. chronic alveolar focal or diffuse, unique or multiple, opacity lasting for more than three weeks, or ii. appearance of a pulmonary opacity in a patient affected by a known extra-pulmonary B-NHL and 2) absence of pulmonary infectious disease or cancer diagnosed by routine endoscopic examination and bronchoalveolar fluid analysis within the first 72 hours following sampling.
Patients suffering from a previously known leukemic form of a B-cell lymphoproliferative disease, i.e. mostly chronic lymphocytic leukemia (CLL), were not included in the study.
Indeed, in CLL, a dominant B-cell clone is usually detected in BAL fluid due to the presence of a highly dominant clone in circulating B-cell repertoire.
The purpose of this study was to define the sensitivity, the specificity and the predictive value of the analysis of lymphocyte clonality in the BAL of patients suspected of pulmonary lymphoma. The analysis of clonality was interpreted without knowledge of the diagnosis as concluded the clinicians. Conversely, the clinical diagnosis relied on usual strategies (see bellow) without taking into account the PCR results. The pulmonary diagnosis which was recorded for the study was established within 6 months after admission of patient.
The patients were separated in two groups: Group I, patients without previously diagnosed lymphoproliferative disorder and Group II, patients having B-cell lymphoproliferative disease
For personal use only. on October 17, 2017 . by guest www.bloodjournal.org From previously diagnosed before the pulmonary disease occurrence. The diagnosis of primary pulmonary lymphoma was made histologically and in the absence of any other localization of the lymphoma during the three months following the diagnosis (2) . When the lung was the principal tumor site, multifocal MALT NHL was also classified as primary pulmonary lymphoma (3). The diagnosis of secondary pulmonary lymphoma could be made by (i) a pulmonary biopsy or (ii) a lymph node biopsy when the pulmonary lesions waned under lymphoma treatment or progressed and/or relapsed with progression and/or relapse of the lymphoma in other sites. The diagnostic process of other lung diseases was made according to the American Thoracic and European Respiratory Societies recommendations (26) .
Bronchoalveolar lavage procedure
Bronchoalveolar lavage was done using a fiberoptic bronchoscope wedged into the most extensively involved pulmonary segment as seen on thoracic CT scan. Sterile saline was instilled in four aliquots of 50 ml and the fluid was recovered by gentle aspiration.
Specific staining and culture for viruses, bacteria, mycobacteria, and fungi were routinely set up for all samples. Cytological analysis, with differential cell count including lymphocytes was performed on Giemsa-stained cytocentrifuged preparations. The presence of atypical lymphocytes in the cytological analysis was recorded. Lymphocyte subsets were determined by flow cytometry (EPICS ELITE Beckman-Coulter USA). Lymphocytes were stained by anti -CD3, anti-CD4 and anti-CD8 specific monoclonal antibodies for T lymphocytes and by anti CD19 for B lymphocytes (Beckman Coulter France).
Samples
Ten milliliters of fresh bronchoalveolar fluid were referred to the immunological department for PCR analysis. Cells were centrifuged into pellets and kept at 4°C until final inclusion (see inclusion criteria).
Blood and bronchoalveolar fluid samples were analyzed simultaneously.
Frozen biopsies of diagnostic tissue were retrospectively analyzed when available.
Only specimens already acquired for routine diagnosis were used in the study. As 3ZMHJP ), patients were informed that part of the specimens could be used for molecular analysis provided that all routine examinations have been performed.
Histological studies
Bronchial and transbronchial pulmonary biopsies were obtained during bronchoscopy as For immunoglobulin gene rearrangement study, two PCR analysis were performed as previously described (29) (Figure 1a) . In one PCR, the 5' sens oligonucleotide matched homologous sequences within the framework 2 region (30); in the second PCR it matched homologous sequences within the framework 3 region (21). In the two PCR, the 3' antisens oligonucleotide hybridized the JH region (31) .
Clonality analysis
For CDR3 length diversity analysis, the amplified products were run on an ABI prism 310 genetic Analyzer (Applied Biosystems). Results were analyzed using Genscan analysis software (Applied Biosystems). Samples with a unique dominant peak within the polyclonal background ( Figure 1 d, e) were considered as clonal and the clonal population was characterized by its CDR3 size. A peak was "strong" when it was associated with a low or absent polyclonal background (Figure 1d When sample were available, the B-cell repertoire pattern in diagnostic biopsies and/or blood samples was compared with that in alveolar lymphocytes. In a patient, two dominant B-cell populations were considered identical when they displayed the same CDR3 size (figure 2).
When a dominant peak was detected in a lymphoma biopsy it was assumed to characterize the tumoral population. 
Statistical analysis
Student's t test was used to compare means. Chi square or Fisher's exact test was used to compare categorical data when appropriate. Significance was set at p<0.05. Analysis was done using Statview 5.0 (SAS Institute Inc., Cary, NC, USA).
Sensitivity (%) = true positive × 100/true positive + false negative ; specificity (%) = true negative × 100/true negative + false positive; Negative predictive value of a test is the proportion of times that a patient will be confirmed negative for disease when the test is negative and is estimated using the formula: NPV = true negative × 100/true negative + false negative. To determine this parameters, only patients with unpreviously diagnosed B-NHL were considered. In this group, positive diagnosis of primary pulmonary lymphoma was made by the histological examination of pulmonary biopsy, the gold standard criteria. For other diagnosis, biopsy was made as recommended (26) .
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Results
Patient characteristics
One hundred and six patients with a clinical suspicion of pulmonary NHL were included in the study. The diagnosis of pulmonary lesions in these 106 patients, as obtained by usual strategies without taking into account the PCR results, is shown in Table 1 . Eighty two patients had no previous history of lymphoproliferative disorder before the pulmonary symptoms occurred. A thoracic biopsy was performed to establish the diagnosis in 43 patients (41 pulmonary and 2 bronchial biopsies), including all cases with a diagnosis of pulmonary lymphoma. Thirteen patients had a primary pulmonary B-NHL, 10 of whom with a MALT histology, either with pulmonary involvement alone (n=6) or associated with asymptomatic gastric (n=2), salivary and/or parotid gland localization (n=2). Three had diffused large B-NHL. Infectious and autoimmune pulmonary diseases were otherwise the two main diagnoses.
Six patients lost from follow-up are considered as having undetermined diagnosis (Table 1) .
Twenty four patients had a previously diagnosed B-cell lymphoproliferative disorder, either ongoing when pulmonary lesions occurred (n=13) or previously treated with a suspicion of relapse (n=11) ( Table 1) . A thoracic biopsy (8 pulmonary, 1 bronchi and one mediastinal lymph node) was performed in 10 of these patients. Nine patients were considered as having a secondary pulmonary localization demonstrated either histologically in 6 cases or clinically in 3 cases (see criteria in patients and study design). Three patients were considered to have an undetermined diagnosis.
None of the clinical symptoms (cough, dyspnoea, chest pain) or radiological patterns (alveolar opacities, interstitial opacities, pleural effusion) was significantly associated with pulmonary NHL diagnosis, in accordance with previously reported data (reviewed by Cadranel et al (3)).
Cytology in BAL fluid was available in 97 patients and the percentage of lymphocytes is shown in Table 2 .
The presence of atypical lymphocytes in the bronchoalveolar fluid was noted in 9/20 (45%) of patients with "pulmonary B-NHL" and 1/71 (1%) in patients without lymphoma. Lymphocyte phenotypic analysis was performed in 39 cases and showed a predominant T-cell infiltrate except in 4 cases of primary pulmonary lymphoma where B-cells were in excess (Table 2) . Table 3 ). The detection of a dominant B-cell clone in BAL fluid was highly correlated with the detection of a dominant clone in the diagnostic biopsy (p<0.001). When detected, the CDR3 size of the dominant peaks was identical in the two samples. Furthermore, in 6 out of the 8 patients with a same sized dominant peak in BAL fluid and Biopsy, we determined the CDR3 nucleotide sequences of the two peaks. For 2 patients, BAL fluid DNA was no longer available. As shown in Table 4 , the CDR3 nucleotide sequences were identical between the two samples in 6 / 6 studied cases.
The detection or the non detection of a dominant peak was identical in biopsies and BAL fluid in 15/18 studied patients (83%). Out of the three non concordant results, one patient had a pulmonary lymphoma with a clonal pattern in the biopsy and an oligoclonal pattern in the BAL fluid. A peak with an identical CDR3 size to the "tumoral" peak was found in the BAL fluid, but in the absence of a unique expansion, it was not possible to assume that it was the tumoral clone.
A clonal B-cell population in the BAL fluid could reflect a highly restricted circulating B-cell repertoire as seen in chronic lymphocytic leukemias. Therefore, patients with a known chronic lymphocytic leukemia were not included in the study and clonality in blood was assessed in 41 patients with available blood samples and compared to BAL fluid clonality (Table 5 ). This series included 29 patients with previously undiagnosed NHL and 12 patients with a previously diagnosed B-cell lymphoproliferative disorder. Of the 41 patients, six patients whose diagnosis is given in Table 5 Table 6 ). The sensitivity and specificity of BAL fluid clonality analysis with regard to the detection of a pulmonary lymphoma was determined from the 70 patients with previously undiagnosed B-NHL, whose diagnosis were ascertained and whose BAL fluid clonality were determined (82-6-6=70 patients) (Table 6 ). Indeed, in this group, diagnosis was made using established criteria, including histology when necessary (half of patients), and particularly for all primary pulmonary lymphomas. A clonal pattern could be demonstrated in 18/70 BAL fluids. The presence of a clonal pattern in BAL fluid was statistically more frequent in the pulmonary B-NHL group (10/12 vs. 8/58, p<0.0001) (Table 6 ).
Then, the peak intensity of strong or weak type (see material and methods) was noted and the clinical relevance of a strong clonal pattern was analyzed ( Table 6 ). The specificity of a strong clonal pattern was 97% (56/56+2), with high 82% (9/9+2) and 95% (56/56+3) positive and negative predictive values, respectively. Therefore, the detection of a strong clonal population in BAL fluid is a good argument for the diagnosis of pulmonary lymphoma, and conversely, in the absence of either a strong or weak clonal population in BAL fluid, the probability to have a pulmonary lymphoma is very low.
A weak monoclonal B-cell expansion was found with high frequency (38%) in patients with an autoimmune disease involving the lungs, i.e. 2 Sjögren's syndromes, 2 pulmonary vasculites and one dermatopolymyositis. 
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Within the group of 20 patients with a previously diagnosed B-cell lymphoproliferative disorder whose pulmonary diagnosis were ascertained and whose BAL fluid clonality were determined (24-3-1=20 patients), the detection of a clonal population in BAL fluid also was associated with the diagnosis of pulmonary B-NHL ( 6/8 vs 2/12 p<0.01) ( Table 6 ).
Because Genscan software only analyzes CDR3 length diversity, one can not exclude that one dominant peak includes several clones which present the same CDR3 size. We could further analyzed clonality of 25/29 dominant peaks detected in BAL fluid (19 strong dominant peaks and 6 weak dominant peaks). The clonal nature of 19 strong dominant peak was established in 18/19 patients either by CDR3 nucleotide sequencing (n=10, Table 4 ), or heteroduplex analysis (n=8, data not shown). In 1/19 patient peak monoclonality could not be ascertained by heteroduplex analysis. In this case, Genscan peak intensity was borderline between strong and weak peak and the patient presented an infectious pneumonia. In the 6 weak dominant peaks, in only one patient heteroduplex analysis showed a monoclonal band with a faint intensity (data not shown). Interestingly, this patient had a primary pulmonary lymphoma, and again, Genscan peak intensity was borderline between strong and weak peak. 
Discussion
The diagnosis of pulmonary lymphoma may be evoked in two clinical settings: primary pulmonary lymphoma or pulmonary localization of an otherwise extended NHL. Whether primary or secondary, the demonstration of pulmonary involvement by lymphoma is difficult and the presence of a clonal B-cell population in alveolar lymphocytes may be of indirect value for the diagnosis of pulmonary lymphoma (27, 16, 15, 17) . In the first clinical setting, the detection of a B-cell clone in BAL fluid would argue for the initiation of invasive investigations as transbronchial or surgical biopsies for both histological analysis and immunohistological staining (3, 5, 6) . In the second clinical setting, in the absence of chronic lymphocytic leukemia, the detection in the BAL fluid of the same B-cell clone as in an extrapulmonary NHL lesion would be sufficient for the diagnosis of pulmonary involvement and would avoid the more invasive investigations. In order to assess both the feasibility in routine practice of the clonality analysis and the diagnostic value of B-cell clonality in BAL fluid, a prospective study was carried out including patients in whom pulmonary lymphoma was A first hypothesis to explain this false negative result with regard to the diagnosis of lymphoma is the failure to amplify the malignant cell immunoglobulin gene rearrangement.
Indeed, the incidence of detected clonal immunoglobulin gene rearrangement by PCR in B-NHL varies with the malignant cell differentiation status, particularly their pre or post germinal center phenotype which correlates with the somatic mutation rate (34). Using two PCRs (FR2/JH, FR3/JH) we analyzed lymphomatous biopsies from 11 patients and found a dominant B-cell clone in 10/11 samples (90%), in accordance with previously reported data in MALT, follicular and diffuse large B cell lymphomas (21) . A second hypothesis is the lack of sensitivity of the technique. Indeed, clonality analysis aims at the detection of a dominant clonal population relative to other B-cells in the sample and could fail to detect a minority of malignant B-cells.
In the 18 patients in whom biopsy was analyzed, the B-cell clonality in BAL fluid compared to the biopsy with a correlation of 83%. In two patients, the presence of a tumoral population in BAL fluid could not be demonstrated despite the characterization of the CDR3 size of dominant B-cell population in the tumoral biopsy and the detection of a peak of the same CDR3 size but non dominant in the BAL fluid. This underlines the limit of the technique which characterizes a clone only by its CDR3 size and not by its CDR3 sequence as denaturing gradient gel electrophoresis (DGGE) does (35) . However, the DGGE technique detects intra-clonal diversity due to ongoing somatic mutations which characterizes germinal center derived lymphomas and has been reported in pulmonary MALT lymphomas (36) .
Intraclonal diversity could result in an oligoclonal pattern of the PCR product analysis, thus being useless for the diagnosis of NHL.
A detectable B-cell clone in BAL fluid does not mean a pulmonary B-NHL. Thus, eight out of 58 patients (14%) with non lymphomatous pulmonary lesions were found to have a dominant B-cell population in the BAL fluid. Interestingly, in 6 of the 8 patients, the peak in Genscan analysis was of weak intensity suggesting a minor dominant B-cell clone. This minor dominant B-cell clone were not observed in the 5 cases further analyzed by heteroduplex. The more likely hypothesis is that heteroduplex analysis is less sensitive than Genscan analysis, i.e. can not detect faint clonal population in a high polyclonal background, but one cannot exclude that some of those weak peaks are truly oligoclonal. Moreover, 2/8 patients had a peak of strong intensity with one of the two peaks not detected by heteroduplex analysis. The latter was retrospectively of borderline intensity between strong and weak. Thus, we can hypothesized that if the "strong or weak" classification is refined by a heteroduplex analysis of borderline cases, the predictive value of "strong" peak would be enhanced. Of note, none of those 8 patients have developed a lymphoma with a median follow-up of 4 years after inclusion. Longer follow-up is ongoing.
From the eight patients with a dominant B-cell population in the BAL fluid and non lymphomatous pulmonary lesions, five patients had diffuse interstitial pneumonia associated with an auto-immune disease, and one had an infectious pneumonia. Chronic antigenic In conclusion, our study is the first prospective study using PCR for alveolar lymphocyte clonality analysis in a large population of patients included on the basis of clinical criteria. We show on one hand that the detection of a strong peak in PCR product, i.e. a major clonal B lymphocyte population in the BAL fluid, has good positive and negative predictive values in the diagnosis of pulmonary B-NHL. PCR should be performed in order to sustain the biopsy indication in case of an isolated pulmonary lesion and possibly in order to avoid the biopsy in case of pulmonary lesion in an extended B-NHL. On the other hand, a benign minor B-cell clone can be detected notably in autoimmune and chronic infectious diseases, the predictive value of which for developing lymphoma remains to be determined. DNA was extracted from samples and two PCRs were performed using 2 sets of primers (a) (FR3/JH and FR2/JH) in order to amplify all the size-variable CDR3 rearranged regions (FR2: GC(C/T) (C/T)CC GG(A/G) AA(A/G) (A/G)GT CTG GAG TGG; FR3 :ACA CGG C(C/T)(G/C) TGT ATT ACT GT; JH ACCTGAGGAGACGGTGACC) . PCR products were loaded on an ABI prism fragment size gel analysis. Four patterns were observed; when a polyclonal B-cell population was present in the sample, random sizes of all CDR3 regions resulted in a gaussian distribution of peak sizes (b). Several peaks could dominate in a sample without individualization of one peak, reflecting an oligoclonal pattern (c). One peak could be clearly individualized, either with a strongly dominant pattern, i.e. with a low polyclonal background (d) or as a weak dominant peak i.e. with an intense polyclonal background (e). Patterns (b) and (c) were considered as "non-clonal". When pattern (d) or (e) was observed either from FR3/JH or FR2/JH PCR, the sample was considered as "clonal". DNA from BAL fluid, biopsy and blood samples was amplified and PCR products were loaded on an ABI prism fragment size gel analysis. Using size marker (red peak) and Genscan software, CDR3 size of the dominant peak could be determined and compared between different samples in a single patient. In case 1, the same dominant peak can be seen in PCR products obtained from BAL fluid and pulmonary biopsy but not from a blood sample, showing the presence of the same clonal B-cell population in both biopsy lymphocyte infiltrate and BAL fluid. In case 2, no dominant peak was detected in any analyzed tissue.
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